Följ
Cale Fahrenholtz
Cale Fahrenholtz
Assistant Professor at High Point University Fred Wilson School of Pharmacy
Verifierad e-postadress på highpoint.edu
Titel
Citeras av
Citeras av
År
Photothermal therapy of glioblastoma multiforme using multiwalled carbon nanotubes optimized for diffusion in extracellular space
BN Eldridge, BW Bernish, CD Fahrenholtz, R Singh
ACS biomaterials science & engineering 2 (6), 963-976, 2016
762016
Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo
J Swanner, CD Fahrenholtz, I Tenvooren, BW Bernish, JJ Sears, ...
FASEB bioAdvances 1 (10), 639, 2019
682019
Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival
SO Peacock, CD Fahrenholtz, KL Burnstein
Molecular endocrinology 26 (12), 1967-1979, 2012
592012
Heterogeneous responses of ovarian cancer cells to silver nanoparticles as a single agent and in combination with cisplatin
CD Fahrenholtz, J Swanner, M Ramirez-Perez, RN Singh
Journal of Nanomaterials 2017, 2017
532017
A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer
S Rao, LS Lyons, CD Fahrenholtz, F Wu, A Farooq, W Balkan, ...
Oncogene 31 (6), 716-727, 2012
522012
Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer
CD Fahrenholtz, FG Rick, MI Garcia, M Zarandi, RZ Cai, NL Block, ...
Proceedings of the National Academy of Sciences 111 (3), 1084-1089, 2014
482014
Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer
N Zhao, SO Peacock, CH Lo, LM Heidman, MA Rice, CD Fahrenholtz, ...
Science translational medicine 11 (498), eaaw4636, 2019
432019
Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts
CD Fahrenholtz, PJ Beltran, KL Burnstein
Molecular cancer therapeutics 12 (4), 394-404, 2013
422013
Targeting breast cancer with sugar-coated carbon nanotubes
CD Fahrenholtz, M Hadimani, SB King, SV Torti, R Singh
Nanomedicine 10 (16), 2481-2497, 2015
392015
Large‐Pore Functionalized Mesoporous Silica Nanoparticles as Drug Delivery Vector for a Highly Cytotoxic Hybrid Platinum–Acridine Anticancer Agent
Y Zheng, CD Fahrenholtz, CL Hackett, S Ding, CS Day, R Dhall, GS Marrs, ...
Chemistry–A European Journal 23 (14), 3386-3397, 2017
292017
Combined photothermal and ionizing radiation sensitization of triple-negative breast cancer using triangular silver nanoparticles
J Sears, J Swanner, CD Fahrenholtz, C Snyder, M Rohde, ...
International Journal of Nanomedicine, 851-865, 2021
232021
Design and cellular studies of a carbon nanotube-based delivery system for a hybrid platinum-acridine anticancer agent
CD Fahrenholtz, S Ding, BW Bernish, ML Wright, Y Zheng, M Yang, X Yao, ...
Journal of inorganic biochemistry 165, 170-180, 2016
222016
Evaluation of multiwalled carbon nanotube cytotoxicity in cultures of human brain microvascular endothelial cells grown on plastic or basement membrane
BN Eldridge, F Xing, CD Fahrenholtz, RN Singh
Toxicology in Vitro 41, 223-231, 2017
212017
Low doses of silver nanoparticles selectively induce lipid peroxidation and proteotoxic stress in mesenchymal subtypes of triple-negative breast cancer
CM Snyder, MM Rohde, CD Fahrenholtz, J Swanner, J Sloop, GL Donati, ...
Cancers 13 (16), 4217, 2021
102021
A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells
CD Fahrenholtz, AM Greene, PJ Beltran, KL Burnstein
Oncotarget 5 (19), 9007, 2014
102014
Generation of cultured oligodendrocyte progenitor cells from rat neonatal brains
EC Larsen, Y Kondo, CD Fahrenholtz, ID Duncan
Current Protocols in Stem Cell Biology 6 (1), 2D. 1.1-2D. 1.13, 2008
72008
ACS Biomaterials Science & Engineering
BN Eldridge, BW Bernish, CD Fahrenholtz, R Singh
American Chemical Society, 2016
52016
Abstract B05: Self-assembling platinum-acridine loaded carbon nanotubes for triple-negative breast cancer chemotherapy
CD Fahrenholtz, S Ding, BW Bernish, M Wright, U Bierbach, RN Singh
Molecular Cancer Research 14 (2_Supplement), B05-B05, 2016
32016
Abstract B04: systemic delivery of silver nanoparticles and targeting of the folate receptor alpha for the treatment of triple-negative breast cancer
JL Swanner, CD Fahrenholtz, RN Singh
Molecular Cancer Research 14 (2_Supplement), B04-B04, 2016
22016
Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors in a Neurofibromin-Dependent Manner
G Alewine, J Knight, A Ghantae, C Mamrega, B Attiah, RA Coover, ...
Journal of Personalized Medicine 12 (7), 1080, 2022
12022
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20